Piramal Realty

Mumbai, India Founded: 2010 • Age: 16 yrs Listed
Development services for residential, commercial, and mixed-use projects are provided.
Request Access
Report Incorrect Data
Page last updated

About Piramal Realty

Piramal Realty is a publicly listed company based in Mumbai (India) founded in 2010 by Anand Piramal. Development services for residential, commercial, and mixed-use projects are provided. Piramal Realty has raised $150.33 million across 2 funding rounds from investors including Goldman Sachs. The company has 5,480 employees. Its chief executive, as recorded, is Abhijeet Maheshwari. Its website piramalrealty.com draws about 18 thousand monthly visits. Its Indian entity Piramal Pharma Limited reported revenue of ₹9,161 Cr. Piramal Realty offers products and services including Piramal Aranya, Piramal Mahalaxmi, Piramal Vaikunth, Piramal Revanta, and Piramal Agastya. Its focus areas include Real Estate and Construction, Real Estate & Infrastructure Developers and Diversified. Its competitors include Lodha Group, Godrej Properties and DLF India.

Company details

Piramal Realty was established in 2010 in Mumbai, India. Real estate development is focused on residential, commercial, and mixed-use projects. Operations are conducted within the Indian property sector, with services encompassing project planning and execution. The company is led by founder Anand Piramal and CEO Abhijeet Maheshwari. Headquarters are maintained in Mumbai.

Recognitions & Rankings of Piramal Realty

India's Most Valuable Companies 2021 edition · Source: Hurun India
Rank#283
Valuation
₹12,000 Cr
  • Headquarters Mumbai, India
  • Employees 5,480
  • Founders Anand Piramal
  • Stage Public
  • Sectors
    Real Estate & Construction
  • Website category Business and Consumer Services · Real Estate
  • Email
    ••••••••
  • Website piramalrealty.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Piramal Pharma Limited
  • Date of Incorporation 04 Mar, 2020
  • Jurisdiction Mumbai, Maharashtra, India
Operational Areas
Real Estate & Construction → Real Estate Developers & Builders
Key Metrics
  • Market Cap
    ₹32,800 Cr

    PPLPHARMA · NSE

  • Share Price
    ₹246.37

    +0.07% today

  • Revenue
    ₹8,869 Cr

    FY 2025-26 · -3.1% YoY

  • EBITDA
    ₹704 Cr

    Margin 7.9%

  • Net Profit
    −₹312 Cr

    FY 2025-26 · -451.5% YoY

  • ROE
    -3.8%

    ROCE 2.5%

  • Debt / Equity
    0.65

    Interest cover -267.9x

  • Total Equity Funding
    $150.33M (USD)

    in 2 rounds

  • Latest Funding Round
    $150M (USD), Series A

    Aug 2015

  • Investors
    Goldman Sachs
  • Employee Count
    5,480

Products & Services of Piramal Realty

Piramal Realty offers a comprehensive portfolio of products and services, including Piramal Aranya, Piramal Mahalaxmi, Piramal Vaikunth, Piramal Revanta, and Piramal Agastya.

Piramal Aranya
Luxury Residential Project

Offers luxury apartments in Byculla, Mumbai for high-end living.

Piramal Mahalaxmi
Luxury Residential Project

Provides upscale residences in Mahalaxmi, Mumbai with modern amenities.

Piramal Vaikunth
Luxury Residential Project

Features apartments and townhomes in Thane for family-oriented spaces.

Piramal Revanta
Luxury Residential Project

Delivers studio to multi-bedroom units in Mulund, Mumbai.

Piramal Agastya
Luxury Residential Project

Includes residential developments in Kurla, Mumbai with quality designs.

Apps and channels of Piramal Realty

its YouTube channel Piramal Realty has 6.06K subscribers and 30 videos.

Piramal Realty
YouTube 6.06K subscribers 30 videos Howto & Style
Open channel

Videos from Piramal Realty

The most watched videos on Piramal Realty's YouTube channel, Piramal Realty (6.06K subscribers). Click a video to play it here.

Piramal Aranya | Now Launching AHAN 2
508.1K views
Piramal Vaikunth | Construction Update | April 2025
1.7K views
Piramal Vaikunth Construction Update | July 2025
1.6K views
The Sharma Family Story in Full Bloom at Piramal Aranya.
1.5K views

More on Piramal Realty.

Funding Insights of Piramal Realty

Piramal Realty has successfully raised a total of $150.33M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $150 million completed in August 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $150.33M
  • Total Rounds 2
  • Last Round Series A — $150M
  • First Round $330,062

    (Jun 2011)

  • Investors Count 1

All 2 funding rounds of Piramal Realty with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2015$150MSeries A–Goldman Sachs
–
Jun 2011$330,062Seed––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Piramal Realty

Piramal Realty has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Goldman Sachs.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Goldman Sachs
Investment banking services are delivered across multiple financial sectors.
1869goldmansachs.comNew York, United States
Premium access

Investor details for Piramal Realty

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Piramal Pharma Limited (Piramal Realty)

Piramal Pharma Limited is the primary company behind Piramal Realty. The boards of the 4 registered companies of Piramal Realty currently have 22 directors; the longest-serving is Khushru Burjor Jijina, appointed in 2017. 33 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Khushru Burjor Jijina
DIN 00209953
Managing Director10 Feb 20179 yrs 8 moPiramal Capital & Housing Finance Limited
Suhail Amin Nathani
DIN 01089938
Director08 Sep 20179 yrs 2 moPiramal Capital & Housing Finance Limited
Anand Ajay Piramal
DIN 00286085
Director28 May 20188 yrs 5 moPiramal Capital & Housing Finance Limited
Ajay Gopikisan Piramal
DIN 00028116
Director28 May 20188 yrs 5 moPiramal Capital & Housing Finance Limited
Swati Ajay Piramal
DIN 00067125
Director28 May 20188 yrs 5 moPiramal Capital & Housing Finance Limited
Sachin Prabhakar Deodhar
DIN 00319687
CFO28 May 20188 yrs 5 moPiramal Capital & Housing Finance Limited
Gautam Bhailal Doshi
DIN 00004612
Director29 Jul 20197 yrs 3 moPiramal Capital & Housing Finance Limited
Peter D Deyoung
DIN 07152550
Whole-time director04 Mar 20206 yrs 8 moPiramal Pharma Limited
Nandini Ajay Piramal
DIN 00286092
Whole-time director04 Mar 20206 yrs 8 moPiramal Pharma Limited
Bipin Singh
DIN 00058068
Company Secretary08 May 20206 yrs 6 moPiramal Capital & Housing Finance Limited
Jairaj Manohar Purandare
DIN 00159886
Director09 Feb 20215 yrs 9 moPiramal Pharma Limited
Sarita Shrinivas Iyer
DIN 07328713
Director23 Aug 20215 yrs 2 moPiramal Realty & Developers Private Limited
Vivek Valsaraj
DIN 06970246
Whole-time director09 Feb 20224 yrs 9 moPiramal Pharma Limited
Sridhar Gorthi
DIN 00035824
Director30 Mar 20224 yrs 7 moPiramal Pharma Limited
Peter Andrew Stevenson
DIN 09544706
Director30 Mar 20224 yrs 7 moPiramal Pharma Limited
Vibha Paul Rishi
DIN 05180796
Director30 Aug 20224 yrs 2 moPiramal Pharma Limited
Sunilkumar Jagdishprasad Adukia
DIN 00020049
Director10 May 20233 yrs 6 moPrpl Enterprises Private Limited
Vinod Damodar Gadaiya
DIN 09834680
Director10 May 20233 yrs 6 moPrpl Enterprises Private Limited
Nathalie Ann Leitch
DIN 09557042
Director28 Jan 20251 yr 9 moPiramal Pharma Limited
Amit Jain
DIN 06917608
Director14 May 20251 yr 5 moPiramal Pharma Limited
Vandana Jitendra Chablani
DIN 03603877
Director16 Jun 20251 yr 4 moPiramal Realty & Developers Private Limited
Amit Soni
DIN 05111144
Director09 Feb 20269 moPiramal Pharma Limited

People of Piramal Realty

3 people are tracked at Piramal Realty (2 in leadership, 1 in team); the tracked headcount is 5,480.

NameRoleGroup
Anand Piramal
FounderLeadership
Abhijeet Maheshwari
CEOLeadership
Ajay Piramal
ChairmanTeam
Premium access

Complete people profiles for Piramal Realty

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Piramal Realty

Piramal Realty is a publicly listed company on the NSE with ticker symbol PPLPHARMA in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: PPLPHARMA
  • Listed entityPiramal Pharma Limited
  • Exchange sectorPharmaceuticals

Financials of Piramal Realty

Exchange-reported figures of Piramal Pharma Limited, the listed company behind Piramal Realty (NSE: PPLPHARMA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹8,869 Cr
-3.1% YoY
EBITDA
₹704 Cr
-51.3% YoY
Profit After Tax
−₹312 Cr
-451.5% YoY
Net Worth
₹8,163 Cr
+0.5% YoY
Total Assets
₹14,088 Cr
+6.7% YoY
Total Debt
₹5,675 Cr
+16.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue8,8699,1518,1717,0826,5596,315
Revenue growth-3.1%+12.0%+15.4%+8.0%+3.9%-
EBITDA7041,4451,1336219351,428
EBITDA margin+7.9%+15.8%+13.9%+8.8%+14.3%+22.6%
Profit before tax(176)415179(120)485949
Net profit(312)88.8215.83(186)384818
Net profit margin-3.5%+1.0%+0.2%-2.6%+5.9%+13.0%
EPS (₹)(2.46)0.690.13(1.56)3.178.40
Balance sheet
Total assets14,08813,20612,82212,61210,9918,780
Net worth8,1638,1257,9116,7746,6975,605
Total debt5,6754,8564,7105,6374,1283,025
Cash & bank1,224501483308329406
Net working capital3,5413,5543,0592,7172,4031,751
Cash flow
Cash from operations1,6538921,005484766598
Cash from investing(820)(488)(416)(1,334)(1,737)(4,464)
Cash from financing(38.98)(441)(422)8187943,977
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,6172,2702,7522,1402,0441,9342,7542,204
Revenue growth (YoY)+28.1%+17.4%-0.1%-2.9%-8.8%-0.9%--
Other income53.6710959.6353.5080.3997.7158.2529.18
EBITDA349195285155159107561338
EBITDA margin+13.3%+8.6%+10.3%+7.2%+7.8%+5.5%+20.4%+15.3%
Depreciation233224218213203197243197
Interest87.6388.0882.9989.2482.4286.15104103
Profit before tax81.63(7.46)43.00(93.86)(46.18)(79.02)27366.80
Tax76.6061.9351.8342.3353.042.6811963.12
Net profit5.03(69.39)(8.83)(136)(99.22)(81.70)1543.68
EPS (₹)0.04(0.52)(0.07)(1.03)(0.75)(0.62)1.160.03
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue4,7825,2864,3903,4433,3402,939
Revenue growth-9.5%+20.4%+27.5%+3.1%+13.7%-
EBITDA5491,04061890.57460619
EBITDA margin+11.5%+19.7%+14.1%+2.6%+13.8%+21.1%
Profit before tax877911508124462687
Net profit76868938872.64378556
Net profit margin+16.1%+13.0%+8.8%+2.1%+11.3%+18.9%
EPS (₹)5.275.222.960.583.105.75
Balance sheet
Total assets9,0228,7447,9216,9366,3004,281
Net worth8,1417,4536,7125,2625,1234,101
Total debt7861,2431,1771,6491,164174
Cash & bank57417824264.16137152
Net working capital1,8422,1011,7971,3371,166463
Cash flow
Cash from operations1,32854935871.5224934.72
Cash from investing(318)(552)(635)(435)(1,165)(4,383)
Cash from financing(615)(61.74)4512908964,494
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,3451,1251,4891,1961,1279701,6901,248
Revenue growth (YoY)+19.4%+16.0%-11.9%-4.2%-12.2%-8.8%--
Other income13811518496.1520218139.5124.70
Total expenses1,1741,0081,2511,0561,0009261,2731,029
EBITDA17211723814012744.33417219
EBITDA margin+12.7%+10.4%+16.0%+11.7%+11.3%+4.6%+24.7%+17.6%
Depreciation67.5665.7370.1264.6961.2559.4461.1755.46
Interest17.2716.3619.5016.8420.3823.2330.5629.17
Profit before tax225149332155247143364159
Tax53.8636.0070.2226.0251.0829.4487.0940.61

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,6172,2702,7522,1402,0441,9342,7542,204
Revenue growth (YoY)+28.1%+17.4%-0.1%-2.9%-8.8%-0.9%--
Other income53.6710959.6353.5080.3997.7158.2529.18
EBITDA349195285155159107561338
EBITDA margin+13.3%+8.6%+10.3%+7.2%+7.8%+5.5%+20.4%+15.3%
Depreciation233224218213203197243197
Interest87.6388.0882.9989.2482.4286.15104103
Profit before tax81.63(7.46)43.00(93.86)(46.18)(79.02)27366.80
Tax76.6061.9351.8342.3353.042.6811963.12
Net profit5.03(69.39)(8.83)(136)(99.22)(81.70)1543.68
EPS (₹)0.04(0.52)(0.07)(1.03)(0.75)(0.62)1.160.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue8,8699,1518,1717,0826,5596,315
Revenue growth-3.1%+12.0%+15.4%+8.0%+3.9%-
Other income292208235279335230
Total expenses8,1657,7067,0386,4605,6254,887
Employee cost2,4162,3072,0301,8961,5891,468
EBITDA7041,4451,1336219351,428
EBITDA margin+7.9%+15.8%+13.9%+8.8%+14.3%+22.6%
Depreciation831816741677586545
Interest341422448344198163
Profit before tax(176)415179(120)485949
Tax15032416166.31109114
Net profit(312)88.8215.83(186)384818
Net profit margin-3.5%+1.0%+0.2%-2.6%+5.9%+13.0%
EPS (₹)(2.46)0.690.13(1.56)3.178.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital1,3271,3241,3231,1931,186995
Reserves & surplus6,8356,8016,5885,5805,5114,610
Shareholders' funds (net worth)8,1638,1257,9116,7746,6975,605
Minority interest0.000.000.000.000.000.00
Secured loans5,4704,5904,5365,4973,9812,601
Unsecured loans204266174140146424
Total debt5,6754,8564,7105,6374,1283,025
Total liabilities14,08813,20612,82212,61210,9918,780
Assets
Gross block14,82913,07712,09910,8429,5108,153
Net block8,6848,1337,9907,4696,8796,105
Capital work in progress1,1009771,1161,4191,172627
Investments437291385639267123
Inventories3,0642,3132,1761,6811,3891,232
Sundry debtors2,1582,3502,1341,7991,7851,575
Cash & bank balances1,224501483308329406
Loans & advances614614527620514436
Total current assets7,0605,7775,3204,4084,0173,649
Total current liabilities3,5192,2232,2611,6911,6141,898
Net working capital3,5413,5543,0592,7172,4031,751
Total assets14,08813,20612,82212,61210,9918,780
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash18221953.2385.18262152
Net cash from operating activities1,6538921,005484766598
Net cash from investing activities(820)(488)(416)(1,334)(1,737)(4,464)
Net cash from financing activities(38.98)(441)(422)8187943,977
Net change in cash794(36.87)166(31.95)(177)110
Closing cash1,224501483308329406
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-3.1%+12.0%+15.4%+8.0%+3.9%-
EBITDA growth-51.3%+27.5%+82.4%-33.5%-34.6%-
PBT growth-+131.3%+9998.0%--48.9%+9997.0%
Net income growth-451.5%+461.1%+108.5%-148.4%-53.0%-
Revenue CAGR (3Y)+7.8%+11.7%+9.0%---
EBITDA CAGR (3Y)+4.3%+15.6%-7.4%---
Profitability & leverage
Net income margin-3.7%+1.0%+0.2%-2.6%+5.7%+13.2%
Return on capital employed+2.5%+6.4%+5.4%+1.9%+6.9%+12.7%
Return on net worth-3.8%+1.1%+0.2%-2.8%+6.1%+14.9%
Debt / equity0.650.600.700.720.580.54
Long-term debt / equity0.480.370.410.460.420.43
Interest cover-267.9567.08114.15-621.1556.9018.51
Efficiency & per share
Fixed asset turnover0.640.730.710.700.740.77
Inventory turnover3.304.084.244.615.015.13
Debtors turnover3.944.084.153.953.904.01
EPS (₹)(2.46)0.690.13(1.56)3.178.40
Dividend per share (₹)0.000.140.110.000.560.00
Book value per share (₹)61.5061.3559.8056.7656.4756.35
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,3451,1251,4891,1961,1279701,6901,248
Revenue growth (YoY)+19.4%+16.0%-11.9%-4.2%-12.2%-8.8%--
Other income13811518496.1520218139.5124.70
Total expenses1,1741,0081,2511,0561,0009261,2731,029
EBITDA17211723814012744.33417219
EBITDA margin+12.7%+10.4%+16.0%+11.7%+11.3%+4.6%+24.7%+17.6%
Depreciation67.5665.7370.1264.6961.2559.4461.1755.46
Interest17.2716.3619.5016.8420.3823.2330.5629.17
Profit before tax225149332155247143364159
Tax53.8636.0070.2226.0251.0829.4487.0940.61
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue4,7825,2864,3903,4433,3402,939
Revenue growth-9.5%+20.4%+27.5%+3.1%+13.7%-
Other income663207202341225216
Total expenses4,2334,2453,7723,3532,8802,320
Employee cost745736614548448395
EBITDA5491,04061890.57460619
EBITDA margin+11.5%+19.7%+14.1%+2.6%+13.8%+21.1%
Depreciation256222205192165144
Interest79.9511510711657.294.71
Profit before tax877911508124462687
Tax17722011654.1994.79115
Net profit76868938872.64378556
Net profit margin+16.1%+13.0%+8.8%+2.1%+11.3%+18.9%
EPS (₹)5.275.222.960.583.105.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital1,3271,3241,3231,1931,186995
Reserves & surplus6,8146,1285,3894,0683,9373,106
Shareholders' funds (net worth)8,1417,4536,7125,2625,1234,101
Secured loans4211,0098961,3131,15490.20
Unsecured loans36523428133610.6984.06
Total debt7861,2431,1771,6491,164174
Total liabilities9,0228,7447,9216,9366,3004,281
Assets
Gross block4,5754,2493,7673,5653,2252,260
Net block3,0362,8942,6122,6022,4391,627
Capital work in progress221327533417405121
Investments3,5803,1051,7081,7471,6301,592
Inventories1,8731,2051,153819536421
Sundry debtors1,4061,6671,331910989840
Cash & bank balances57417824264.16137152
Loans & advances451486504456403355
Total current assets4,3053,5363,2302,2492,0651,768
Total current liabilities2,4621,4341,4339128991,305
Net working capital1,8422,1011,7971,3371,166463
Total assets9,0228,7447,9216,9366,3004,281
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash16422954.281281470.74
Net cash from operating activities1,32854935871.5224934.72
Net cash from investing activities(318)(552)(635)(435)(1,165)(4,383)
Net cash from financing activities(615)(61.74)4512908964,494
Net change in cash395(64.93)175(73.41)(19.03)146
Closing cash57417824264.16137152
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-9.5%+20.4%+27.5%+3.1%+13.7%-
EBITDA growth-47.2%+68.4%+582.3%-80.3%-25.7%-
PBT growth-3.8%+79.5%+310.4%-73.3%-32.7%+9997.0%
Net income growth+11.4%+77.6%+434.0%-80.8%-32.0%-
Revenue CAGR (3Y)+11.6%+16.5%+14.3%---
EBITDA CAGR (3Y)+82.4%+31.3%-0.1%---
Profitability & leverage
Net income margin+14.6%+13.1%+8.9%+2.0%+11.0%+19.5%
Return on capital employed+10.8%+12.3%+8.3%+3.6%+9.8%+16.2%
Return on net worth+9.0%+9.8%+6.5%+1.3%+8.0%+13.9%
Debt / equity0.130.170.240.270.150.04
Long-term debt / equity0.050.050.080.110.050.00
Interest cover27.1914.0025.95-114.1519.430.99
Efficiency & per share
Fixed asset turnover1.081.321.201.011.221.30
Inventory turnover3.114.484.455.096.996.98
Debtors turnover3.113.533.923.633.653.50
EPS (₹)5.275.222.960.583.105.75
Dividend per share (₹)0.000.140.110.000.560.00
Book value per share (₹)61.3456.2750.7444.0943.2041.23

Timeline of Piramal Realty

3 dated milestones of Piramal Realty across 5 years, from founding to its latest funding, stage changes and deals.

  1. Founded Piramal Realty is founded.
  2. Funding First funding round of $330K.
  3. Funding Latest funding round, Series A, of $150.0M.

Competitors of Piramal Realty

Piramal Realty has 3 listed competitors in our database. They include Lodha Group, Godrej Properties and DLF India.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Lodha Group
lodhagroup.com1980Mumbai, India4,846
Developer of residential and commercial real estate properties
Godrej Properties
godrejproperties.com1990Mumbai, India408
Residential and commercial properties are developed by Godrej Properties.
DLF India
dlf.in1947Gurugram, India132
Provider of property and real estate development services
Premium access

Detailed competitors of Piramal Realty

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Piramal Realty

The website of Piramal Realty (piramalrealty.com) receives about 18.4K visits a month and ranks #1,319,101 among all websites worldwide, #9,989 in Real Estate.

  • Monthly visits
    18.4K

    ▼ 19.2% vs previous month

  • Unique visitors
    8.2K

    per month

  • Global rank
    #1,319,101

    among all websites

  • Category rank
    #9,989

    Business and Consumer Services · Real Estate

Similar websites

Websites whose visitors overlap most with Piramal Realty. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Piramal Aranya
piramalaranya.com
100%
#2,339,316View details
Bombay Realty
bombayrealty.in
96%
15.6K#1,675,369View details
guptasen.com
guptasen.com
92%
#1,022,167–
Mumbai Property Exchange
mumbaipropertyexchange.com
91%
#1,072,323View details
piramalvaikunth.com
piramalvaikunth.com
86%
#5,006,327–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 31 similar websites and full traffic analytics for Piramal Realty

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 31 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Real Estate Developers & Builders

3 companies that operate in the same segment as Piramal Realty (Real Estate Developers & Builders) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Isprava
Developer of luxury residential properties
1992Mumbai, Maharashtra, IndiaUSD 158.42 MUSD 55.39 M1,046
Godrej Properties
Residential and commercial properties are developed by Godrej Properties.
1990Mumbai, Maharashtra, IndiaUSD 546.88 M6,030
Oberoi Realty
Premium residential building development services are provided.
1980Mumbai, Maharashtra, IndiaUSD 152.4 MUSD 658.36 M1,322
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Piramal Realty

Piramal Pharma: Expects EBITDA Margins To Increase In H2 Of The Year
Exchange Update • 13 days ago
PPLPHARMA: Q2 REVENUE 26.2B RUPEES VS 20.4B (YOY)
Exchange Update • 14 days ago
PPLPHARMA: Q2 CONS NET PROFIT 56M RUPEES VS LOSS 992M (YOY); EST LOSS 701M
Exchange Update • 14 days ago
PPLPHARMA: Q2 EBITDA 3.66B RUPEES VS 1.58B (YOY); Q2 EBITDA MARGIN 14% VS 7.73% (YOY)
Exchange Update • 14 days ago
Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility
Business Standard • 1 month ago
Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility - The Wire
The Wire • 1 month ago
Piramal Pharma Solutions Launches New Microbiology Laboratory at Lexington Facility
WebDisclosure • 1 month ago
Piramal Pharma: Sales Deal With Bayer Pharmaceuticals Ends December 31, 2026, Without Renewal.
Exchange Update • 1 month ago
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month - The Wire
The Wire • 1 month ago
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
Business Standard • 1 month ago
Premium access

Complete news archive for Piramal Realty

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Piramal Realty

Piramal Realty was founded in 2010 and raised its 1st funding round 1 year after it was founded.

Piramal Realty is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Abhijeet Maheshwari is the CEO of Piramal Realty, as recorded in our data.

Piramal Realty is a funded company, having raised a total of $150.33M across 2 funding rounds to date. The company's 1st funding round was a Seed of $330.06K, raised on Jun 2011.

Piramal Realty has 5,480 employees.

The primary company behind Piramal Realty, Piramal Pharma Limited, reported revenue of ₹9,161 Cr for FY 2026, down 3% year on year.

Piramal Realty was established in 2010 in Mumbai, India. Real estate development is focused on residential, commercial, and mixed-use projects. Operations are conducted within the Indian property sector, with services encompassing project planning and execution. The company is led by founder Anand Piramal and CEO Abhijeet Maheshwari. Headquarters are maintained in Mumbai.

Piramal Realty's top competitors include Godrej Properties, DLF India and Lodha Group.

Piramal Realty offers Piramal Aranya, Piramal Mahalaxmi, Piramal Vaikunth, Piramal Revanta, and Piramal Agastya.

Yes, Piramal Realty is publicly traded on NSE under the ticker symbol PPLPHARMA.

Piramal Realty has 1 investor. Key investors include Goldman Sachs.

Piramal Realty is associated with 5 legal entities: Piramal Pharma Limited, Piramal Capital & Housing Finance Limited, Piramal Realty & Developers Private Limited and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available